Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study
- PMID: 12352410
- DOI: 10.1016/S0022-5347(05)64466-7
Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study
Abstract
Purpose: Photodynamic therapy, using a photosensitizing drug activated by red light, can destroy localized areas of cancer with safe healing and without the cumulative toxicity associated with ionizing radiation. We used photodynamic therapy in a phase I-II study to treat patients with locally recurrent prostate cancer after radiotherapy.
Materials and methods: Patients with an increasing prostate specific antigen (PSA) and biopsy proven local recurrence after radiotherapy were offered photodynamic therapy. Three days after intravenous administration of the photosensitizer meso-tetrahydroxyphenyl chlorin, light was applied using optical fibers inserted percutaneously through perineal needles positioned in the prostate with imaging guidance. Patients were followed with PSA measurements, prostate biopsies, computerized tomography or magnetic resonance imaging and questionnaires on urinary and sexual function.
Results: Photodynamic therapy was given to 14 men using high light doses in 13. Treatment was well tolerated. PSA decreased in 9 patients (to undetectable levels in 2) and 5 had no viable tumor on posttreatment biopsies. After photodynamic therapy, contrast enhanced computerized tomography or magnetic resonance imaging showed necrosis involving up to 91% of the prostate cross section. In 4 men stress incontinence developed (troublesome in 2 and mild in 2) which is slowly improving. Sexual potency was impaired in 4 of the 7 men able to have intercourse before photodynamic therapy, which did not improve. There were no rectal complications directly related to photodynamic therapy, but in 1 patient a urethrorectal fistula developed following an ill-advised rectal biopsy 1 month after therapy.
Conclusions: Photodynamic therapy is a new option that could be suitable for organ confined prostate cancer recurrence after radiotherapy. With more precise light dosimetry, it may be possible to destroy essentially all glandular tissue within the prostate with few complications. These results suggest that photodynamic therapy merits further investigation.
Similar articles
-
Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer.Lasers Surg Med. 2006 Jun;38(5):356-63. doi: 10.1002/lsm.20275. Lasers Surg Med. 2006. PMID: 16392142 Clinical Trial.
-
Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.J Environ Pathol Toxicol Oncol. 2006;25(1-2):373-87. doi: 10.1615/jenvironpatholtoxicoloncol.v25.i1-2.230. J Environ Pathol Toxicol Oncol. 2006. PMID: 16566729 Clinical Trial.
-
Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.BJU Int. 2008 Aug 5;102(5):556-62. doi: 10.1111/j.1464-410X.2008.07753.x. Epub 2008 May 20. BJU Int. 2008. PMID: 18494829 Clinical Trial.
-
Photodynamic therapy for prostate cancer--a review of current status and future promise.Nat Clin Pract Urol. 2009 Jan;6(1):18-30. doi: 10.1038/ncpuro1274. Nat Clin Pract Urol. 2009. PMID: 19132003 Review.
-
[Clinical and biological surveillance after radiotherapy for localized prostate cancer].Cancer Radiother. 2002 May;6(3):159-67. doi: 10.1016/s1278-3218(02)00151-8. Cancer Radiother. 2002. PMID: 12116841 Review. French.
Cited by
-
Wireless magnetoelectrically powered organic light-emitting diodes.Sci Adv. 2024 Mar 8;10(10):eadm7613. doi: 10.1126/sciadv.adm7613. Epub 2024 Mar 6. Sci Adv. 2024. PMID: 38446883 Free PMC article.
-
Versatile Design of Organic Polymeric Nanoparticles for Photodynamic Therapy of Prostate Cancer.ACS Mater Au. 2023 Nov 6;4(1):14-29. doi: 10.1021/acsmaterialsau.3c00060. eCollection 2024 Jan 10. ACS Mater Au. 2023. PMID: 38221923 Free PMC article. Review.
-
Applications of photodynamic therapy in extramammary Paget's disease.Am J Cancer Res. 2023 Oct 15;13(10):4492-4507. eCollection 2023. Am J Cancer Res. 2023. PMID: 37970368 Free PMC article. Review.
-
The use of nanomaterials in advancing photodynamic therapy (PDT) for deep-seated tumors and synergy with radiotherapy.Front Bioeng Biotechnol. 2023 Oct 2;11:1250804. doi: 10.3389/fbioe.2023.1250804. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37849983 Free PMC article. Review.
-
Recent Studies in Photodynamic Therapy for Cancer Treatment: From Basic Research to Clinical Trials.Pharmaceutics. 2023 Aug 31;15(9):2257. doi: 10.3390/pharmaceutics15092257. Pharmaceutics. 2023. PMID: 37765226 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous